AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02789722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yerba Mate Extract
Description: Yerba Mate extract capsules 750 mg
Study NCT02789722 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 3 capsules, 3 times daily for 28 days.
Study NCT02682329 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogen Peroxide and Hydrogen Peroxide
Description: Hydrogen Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP at home and HP at office
Study NCT02436239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Vilazodone tablets, once daily, oral administration
Study NCT03541577 — intervention group
Intervention type: DEVICE
Intervention: TruePhysioTM Microcatheter
Description: Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
Study NCT03541577 — intervention group
Intervention type: DEVICE
Intervention: Pressure Wire
Description: Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
Study NCT01750021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fat low carbohydrate diet
Description: 70E% fat, 20E% protein, 10E% carbohydrates
Study NCT01750021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low fat high carbohydrate diet
Description: 20E% fat, 20E% protein, 60E% carbohydrates
Study NCT03693027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PTx800 lozenges
Description: PTX800 is a nutritional supplement containing generally recognized as safe designated active ingredients in a rapid melt oral lozenges.
Study NCT03693027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: The placebo of PTX800 is a rapid melt oral lozenge without the active ingredients found in the PTX800 lozenges.
Study NCT01158612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: infusion of Growth hormone in the patella tendon.
Study NCT01158612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Growth Hormone
Description: infusion of Growth hormone in the patella tendon.
Study NCT02051101 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy sample from Port Wine Stain Birthmark
Description: Biopsy sample from Port Wine Stain Birthmark
Study NCT04801914 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous biliary drainage
Description: Collection of peripheral blood samples before and one month after percutaneous biliary drainage performed for patients with malignant obstructive hyperbilirubinemia for further molecular biochemical analysis (measurement of serum matrix metalloproteinase activity).
Study NCT04422587 — intervention group
Intervention type: OTHER
Intervention: RECOP unit patient
Description: All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.
Study NCT04238845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AQSP Administration
Description: Three days treatment of all children with AQSP for SMC
Study NCT04238845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQSP Administration
Description: Three days treatment of all children with AQSP for SMC
Study NCT04238845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation with Plumpy'Doz
Description: Daily supplementation of children with Plumpy'Doz
Study NCT04238845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation with Vitamin A
Description: Single dose supplementation with Vitamin A to all children
Study NCT04238845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation with Vitamin A
Description: Single dose supplementation with Vitamin A to all children
Study NCT04238845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation with Zinc
Description: Daily supplementation with Zinc
Study NCT00624338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 75 mg
Description: 75 milligram (mg) atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
Study NCT00624338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Description: 150 mg atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
Study NCT00624338 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo matched to atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
Study NCT02467114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Description: This method will be applied to measure cortical excitability and as an interference approach; real TMS stimulation will be compared with sham stimulation and no stimulation
Study NCT02467114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham coil stimulation
Description: Stimulation with a sham coil as a comparison
Study NCT02467114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control without stimulation
Study NCT02567695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: Test: GBT440 300 mg capsule (high-strength) Reference: GBT440 100 mg capsule (low-strength)
Study NCT02852369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task Oriented Treatment
Description: The intervention administered during each of the training sessions was modeled after the protocol outlined in Winstein et al. (2013) however implementation was in the participant's home setting and involved tasks in the participant's real world.~The manual entitled, Upper-Extremity Task-Specific Training After Stroke or Disability by Lang and Birkenmeier (2014) was also utilized to give a general overview of task specific training for the upper extremity and to help guide each activity the participant chose to work on.
Study NCT03622645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of Range of Motion with Leap Motion sensor
Description: An ROM measurement method called as HandROM by us will be developed with leap motion sensor
Study NCT02004574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol/betamethasone dipropionate gel
Description: All enrolled subjects will receive Xamiol® gel once daily for 8 weeks during the induction period and then will be assessed according to IGA at the end of 8-week induction period. Those subjects determined to be Responder by IGA will be randomized to one of the following three treatment groups and they will continue their therapy with randomized maintenance regimens for the duration of additional 8 weeks.
Study NCT01926886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w; Trastuzumab 600 mg q3w SC injection will be administered as per the schedule specified in the arm.
Study NCT04264962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yang Yin Fu Zheng Jie Du therapy
Description: Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
Study NCT04264962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine medical care
Description: Routine medical care
Study NCT04264962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine medical care
Description: Routine medical care
Study NCT01609192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrea® (hydroxyurea )
Description: treatment by hydroxyurea (20-30 mg/kg/day) for 6 months
Study NCT05226000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benaglutide Injection
Description: All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing. The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.
Study NCT01034527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training
Description: Combination of exercises and phases to initiate lateral trunk perturbations that force the athlete to decelerate and control the trunk in order to successfully perform the techniques.
Study NCT02957825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous wireless monitoring
Description: Continuous wireless monitoring of vital signs
Study NCT01331005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nepafenac 0.1% drops
Description: One drop three times per day for one year
Study NCT01331005 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nepafenac Vehicle
Description: Placebo
Study NCT00720200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitator-Based intervention
Description: Family Members receiving facilitator-based intervention
Study NCT00720200 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Family Members receiving usual care/clinical interaction
Study NCT04135001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HBM Training
Description: A computer-based training to reduce hostile bias and interpersonal conflict as a mechanism to improve trust and cohesion within an operational military unit across the deployment cycle. The computer training is based on the Go/No-Go task (Fillmore et al., 2006) and Lexical Decision Task (Lepore \& Brown, 2002). The training reduces HAB by affecting two cognitive mechanisms: prime seeking non-hostile concepts when presented with ambiguous cues and conditioning inhibition in response to hostile cues. Thus, the training induces a non-hostile attribution bias while simultaneously training the inhibition of hostile attribution bias and aggressive behavior in response to ambiguous cues.
Study NCT04135001 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Training
Description: Volunteers in the placebo condition will be told to complete the fragments with the first word that comes to mind. This placebo still exposes volunteers to the training stimuli and computer task, but does not train inhibition or selectively prime non-hostility, which are the hypothesized mechanisms of the training.
Study NCT01297790 — intervention group
Intervention type: OTHER
Intervention: Cough Challenge Tests
Description: Inhalational cough challenge tests with capsaicin, bradykinin, Citric acid and prostaglandin E2
Study NCT01297790 — intervention group
Intervention type: OTHER
Intervention: ambulatory cough recording
Description: Cough recording with a portable device to capture cough sounds
Study NCT02096874 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month
Study NCT04412161 — intervention group
Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Living donor liver transplantation
Study NCT05450575 — intervention group
Intervention type: DRUG
Intervention: Amosartan Q tablet
Description: Amlodipine, Losartan, Rosuvastatin
Study NCT02585791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vegetable glycerin
Description: inhaled vegetable glycerin (VG) by vaporing
Study NCT02585791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PG+VG
Description: inhaled PG+VG by vaporing
Study NCT01297790 — intervention group
Intervention type: OTHER
Intervention: Cough questionnaires
Description: Questionnaires designed to study cough. These include Leicester cough questionnaire, cough visual analogue score and cough quality of life questionnaire.
Study NCT01368770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coronary CTA
Description: Coronary CTA using standard protocols
Study NCT01368770 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coronary CTA
Description: Coronary CTA using standard protocols
Study NCT01368770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress MPI SPECT
Description: Stress MPI using standard protocols
Study NCT01368770 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stress MPI SPECT
Description: Stress MPI using standard protocols
Study NCT02838030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: 3 gr per day
Study NCT02838030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for L-arginine)
Description: 3 gr per day
Study NCT02838030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: 3 gr per day
Study NCT02838030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetylsalicylic acid
Description: 3 gr per day
Study NCT00982722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol and calcium carbonate
Description: cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
Study NCT00982722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium carbonate
Description: calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
Study NCT03856450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DTS
Description: Subjects undergo wrist imaging using DTS.
Study NCT03856450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DTS
Description: Subjects undergo wrist imaging using DTS.
Study NCT03209713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV Vaccine Education
Description: A one on one twenty-minute parental educational program (in-person or over the phone) providing facts about HPV, HPV-related cancers, and the HPV vaccine.
Study NCT03856450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: X-ray
Description: Subjects undergo wrist imaging using standard X-ray imaging.
Study NCT03856450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-ray
Description: Subjects undergo wrist imaging using standard X-ray imaging.
Study NCT03856450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI or CT
Description: Subjects may undergo wrist imaging using MRI or CT.
Study NCT03518515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White potato (french fries)
Description: If randomized to this group, participants will be asked to consume 1 serving of French fries (\~300 kcal) each day for 30 days as a part of their usual dietary intake. French fries will be portioned and provided to participants.
Study NCT03518515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White potato (French fries), +seasoning
Description: If randomized to this group, participants will be asked to consume 1 serving of French fries (\~300 kcal) with added potential glycemia modifying seasoning mix each day for 30 days as a part of their usual dietary intake. French fries and seasoning will be portioned and provided to participants.
Study NCT03518515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Almond
Description: If randomized to this group, participants will be asked to consume 1 serving of almonds that is calorically-matched to the French fries (\~300 kcal) serving in the other arms each day for 30 days as a part of their usual dietary intake. Almonds will be portioned and provided to participants.
Study NCT02660658 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intrathecal dexmedetomidine
Description: The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance
Study NCT01381107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual administration once daily for 7 consecutive days.
Study NCT01381107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sublingual administration once daily for 7 consecutive days.
Study NCT02062086 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: deuterated creatine 30 mg
Description: Study participants will take a single oral dose of deuterated creatine 30 mg in capsule form
Study NCT01191593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor-Canal-Blockade with Ropivacaine
Description: US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
Study NCT01191593 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Adductor-Canal-blockade with saline
Description: US-guided Adductor-Canal-blockade with saline
Study NCT03022422 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: TIV
Description: Influenza Virus Vaccine Suspension for Intramuscular Injection
Study NCT03022422 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: High-Dose TIV
Description: High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe for intramuscular injection
Study NCT00964795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection 2mg
Study NCT03245814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Service Dog
Description: A service dog trained to perform tasks that are specific to PTSD
Study NCT02122289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of Smartphone
Description: Weekly questionnaire on smartphone
Study NCT02122289 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No application Smartphone
Description: No weekly questionnaire on smartphone
Study NCT02450357 — intervention group
Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.
Study NCT02450357 — intervention group
Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
Study NCT01708564 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhFVIIa
Description: Patients will be administered low, intermediate and high doses of rhFVIIa
Study NCT03916315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Treatment
Description: The Unified Transdiagnostic Protocol (PUT) is a cognitive-behavioral treatment focused on emotions. The PUT was developed to be applicable to anxiety disorders, mood disorders, as well as other disorders in which anxiety and emotional dysregulation play an important role, such as many somatoform and dissociative disorders.~The PUT proposal includes 8 modules, of which 5 are nuclear, it is recommended to give these modules between 11 to 17 sessions with a duration of one hour each.
Study NCT03577613 — intervention group
Intervention type: PROCEDURE
Intervention: Open radical hysterectomy
Study NCT03577613 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic radical hysterectomy
Study NCT03577613 — intervention group
Intervention type: PROCEDURE
Intervention: Robotically assisted radical hysterectomy
Study NCT02621710 — intervention group
Intervention type: OTHER
Intervention: Questionnaire 3 months post-operatively
Study NCT01213784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: all antidiabetic drugs will be appliable
Description: We expect all participants to be set on insulin during the intervention, however all types of insulin and other antidiabetics can be used goal: Hba1c lower than 7,5%
Study NCT02528539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ITP
Description: The study participants will receive weekly acupuncture treatment plus education on self-management for 10 weeks after axillary node dissection, then a total of five follow up acupuncture treatments once every 3 months at 6, 9, 12, 15, and 18 months. The education and self management will be reinforced monthly by telephone visit.~Acupuncture points include: LI 4, LV3, HT3, SP9, GB 20, KD 3, Yintang, and Ashi points
Study NCT04386824 — intervention group
Intervention type: OTHER
Intervention: Erectil dysfunction
Description: A complete ophthalmological examination including best-corrected visual acuity using the decimal system (BCVA), measurement of intraocular pressure (IOP) and axial length (AL), slit-lamp examination and dilated fundus examination
Study NCT04215809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG2575
Description: APG2575 investigation drug in ramp up dosing
Study NCT01693588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Management Bundle
Description: The Pain Management Bundle will be implemented for all postoperative neurosurgical patients admitted to nursing units at the University of Florida.
Study NCT00397930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Care Control Condition
Description: Cancer survivors assigned to this condition continued with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS program gratis after completing all study requirements.